Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT06796998 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Splenic Marginal Zone Lymphoma
Nodal Marginal Zone Lymphoma

Interventions

BIOLOGICAL: Epcoritamab

Sponsor

Izidore Lossos, MD

Collaborators

[object Object]
[object Object]